

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

DISMISSAL OF CLASS ACTION LAWSUIT

The Lawsuit against the defendants therein (the “**Defendants**”) as disclosed in the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司 (the “**Company**”) dated February 25, 2019 (the “**Announcement**”), including WuXi PharmaTech and five of its then directors and/or members of the senior management and other members of the buyer consortium involved in the Delisting, has been dismissed. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

On October 28, 2020, New York time, the parties to the Lawsuit filed an agreement to the United States District Court for the Southern District of New York (the “**Court**”) pursuant to which the Plaintiff agreed not to appeal the Court’s decision on October 14, 2020 dismissing all claims against the Defendants in the Lawsuit.

Therefore, the Lawsuit has been successfully dismissed.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 30, 2020

As at the date of this announcement, the board of the Company is comprised of Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*